

Fiscal Year 2011 Annual Review of Symlin® (Pramlintide)  
 Oklahoma HealthCare Authority  
 April 2012

**Prior Authorization Criteria**

---

Members with type 1 and 2 diabetes using insulin must:

1. be using a basal-bolus insulin regimen (basal insulin plus rapid acting with meals); and
2. have failed to achieve adequate glycemic control (on basal-bolus regimen) or are gaining excessive weight (on basal-bolus regimen); and
3. receiving ongoing care under the guidance of a health care professional.

Members meeting the following criteria should NOT be considered for Symlin® therapy:

1. Poor compliance with insulin regimen
2. Poor compliance with self-blood glucose monitoring
3. HbA1c > 9%
4. Recurrent severe hypoglycemia requiring assistance in past 6 months
5. Presence of hypoglycemia unawareness
6. Diagnosis of gastroparesis
7. Require use of drugs that stimulate GI motility
8. Pediatric patients (≤ 15 years old)

**Utilization of Symlin®**

---

**Comparison of Fiscal Years**


Fiscal Year	Members	Claims	Cost	Cost/Claim	Perdiem	Units	Days
2010	9	30	\$17,867.04	\$595.57	\$20.97	422	852
2011	8	40	\$21,896.53	\$547.41	\$22.34	361	980
% Change	-11.10%	33.30%	22.60%	-8.10%	6.50%	-14.50%	15.00%
Change	-1	10	\$4,029.49	-\$48.16	\$1.37	-61	128

**Utilization Details FY 2011**

Medication	Claims	Members	Units	Days	Cost	Units/Day	% Cost
SYMLIN INJ 600MCG	8	1	160	240	\$7,785.26	0.67	35.55%
SYMLNPEN 120 INJ 1000MCG	18	5	162	495	\$10,789.81	0.33	49.28%
SYMLINPEN 60 INJ 1000MCG	14	3	39	245	\$3,321.46	0.16	15.17%
<b>TOTALS</b>	<b>40</b>	<b>8*</b>	<b>361</b>	<b>980</b>	<b>\$21,896.53</b>	<b>0.37</b>	<b>100%</b>

\*Total number of unduplicated members

### Demographics of Members Utilizing Symlin®: FY 2011



### Prescribers of Symlin® by Number of Claims: FY 2011

Specialty	Claims
Internist	12
General Pediatrician	11
Family Practitioner	9
Unknown	5
Nurse Practitioner (Other)	3

### Prior Authorization of Symlin®

---

There were a total of 37 petitions submitted for Symlin® during fiscal year 2011. The following chart shows the status of the submitted petitions.

### Status of Petitions for Symlin®: FY 2011

Status	Total PA Count
Approved	11
Denied	5
Incomplete	21

### Conclusion and Recommendations

---

The College of Pharmacy recommends continuing the current criteria for Symlin®.